Sarepta Therapeutics Inc logo

SRPT - Sarepta Therapeutics Inc Share Price

$152.27 -0.7  -0.5%

Last Trade - 29/05/20

Large Cap
Market Cap £9.62bn
Enterprise Value £8.42bn
Revenue £330.1m
Position in Universe 624th / 6364
Unlock SRPT Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Sarepta Therapeutics Inc revenues increased 31% to $113.7M. Net loss decreased 77% to $17.5M. Revenues reflect Product, net increase of 15% to $100.4M. Lower net loss reflects Amortization of in-licensed rights decrease of 23% to $166K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.07 to -$0.23.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


SRPT Revenue Unlock SRPT Revenue

Net Income

SRPT Net Income Unlock SRPT Revenue

Normalised EPS

SRPT Normalised EPS Unlock SRPT Revenue

PE Ratio Range

SRPT PE Ratio Range Unlock SRPT Revenue

Dividend Yield Range

SRPT Dividend Yield Range Unlock SRPT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SRPT EPS Forecasts Unlock SRPT Revenue
Profile Summary

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated June 5, 2013
Public Since June 4, 1997
No. of Shareholders: 196
No. of Employees: 743
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 77,988,744
Free Float (0.0%)
Eligible for
SRPT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SRPT
Upcoming Events for SRPT
Thursday 4th June, 2020
Sarepta Therapeutics Inc Annual Shareholders Meeting
Friday 5th June, 2020 Estimate
Sarepta Therapeutics Inc Annual Shareholders Meeting
Wednesday 5th August, 2020 Estimate
Q2 2020 Sarepta Therapeutics Inc Earnings Release
Thursday 5th November, 2020 Estimate
Q3 2020 Sarepta Therapeutics Inc Earnings Release
Frequently Asked Questions for Sarepta Therapeutics Inc
What is the Sarepta Therapeutics Inc share price?

As of 29/05/20, shares in Sarepta Therapeutics Inc are trading at $152.27, giving the company a market capitalisation of £9.62bn. This share price information is delayed by 15 minutes.

How has the Sarepta Therapeutics Inc share price performed this year?

Shares in Sarepta Therapeutics Inc are currently trading at $152.27 and the price has moved by 30.98% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sarepta Therapeutics Inc price has moved by 18.98% over the past year.

What are the analyst and broker recommendations for Sarepta Therapeutics Inc?

Of the analysts with advisory recommendations for Sarepta Therapeutics Inc, there are there are currently 8 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sarepta Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Sarepta Therapeutics Inc next release its financial results?

Sarepta Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Sarepta Therapeutics Inc dividend yield?

Sarepta Therapeutics Inc does not currently pay a dividend.

Does Sarepta Therapeutics Inc pay a dividend?

Sarepta Therapeutics Inc does not currently pay a dividend.

When does Sarepta Therapeutics Inc next pay dividends?

Sarepta Therapeutics Inc does not currently pay a dividend.

How do I buy Sarepta Therapeutics Inc shares?

To buy shares in Sarepta Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sarepta Therapeutics Inc?

Shares in Sarepta Therapeutics Inc are currently trading at $152.27, giving the company a market capitalisation of £9.62bn.

Where are Sarepta Therapeutics Inc shares listed? Where are Sarepta Therapeutics Inc shares listed?

Here are the trading details for Sarepta Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: SRPT
What kind of share is Sarepta Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Sarepta Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sarepta Therapeutics Inc share price forecast 2020?

Shares in Sarepta Therapeutics Inc are currently priced at $152.27. At that level they are trading at 26.03% discount to the analyst consensus target price of 0.00.

Analysts covering Sarepta Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -6.332 for the next financial year.

How can I tell whether the Sarepta Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sarepta Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 39.12%. At the current price of $152.27, shares in Sarepta Therapeutics Inc are trading at 40.82% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sarepta Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Sarepta Therapeutics Inc.

Who are the key directors of Sarepta Therapeutics Inc?

Sarepta Therapeutics Inc's management team is headed by:

M. Kathleen Behrens - CHM
Douglas Ingram - PRE
Sandesh Mahatme - CFO
David Howton - EVP
Alexander Cumbo - EVP
Mary Gray - IND
Gilmore O'Neill - EVP
Richard Barry - IND
Claude Nicaise - IND
Hans Wigzell - IND
John Martin - IND
William Ciambrone - EVP
Who are the major shareholders of Sarepta Therapeutics Inc?

Here are the top five shareholders of Sarepta Therapeutics Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 8.39% (6.54m shares)
Fidelity Management & Research Company Investment Advisor
Percentage owned: 8.28% (6.46m shares)
Sands Capital Management, LLC Investment Advisor
Percentage owned: 5.65% (4.40m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 4.97% (3.87m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.76% (3.71m shares)
Similar to SRPT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.